7 Marijuana Stocks That Can’t Be Ignored - 2 of 7

#2 - Tilray (NASDAQ:TLRY)

Tilray (NASDAQ: TLRY) - Tilray is a Canadian producer that just went public a few months ago. And while there are some analysts that are wary about valuation (TLRY is currently trading at around 500x sales), it has a business model that might actually make it a better pure play than Canopy. Tilray is the second largest cannabis company in terms of market cap and is already an established medicinal marijuana producer in 10 countries. And it has an existing partnership with pharmaceutical provider Novartis and is aggressively trying to make moves into the recreational space by potentially partnering with major beverage companies. But there’s still that valuation problem. The short-selling firm, Citron Research gave TLRY a $45 price target in August 2018. Currently, it trades around $100 per share and recently jumped 20% in a single day on news that private equity company, Privateer Holdings, would not be selling their shares in the first half of this year.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Current Price

$1.78

Consensus Rating

Hold

Ratings Breakdown

1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.

Consensus Price Target

$2.71 (52.2% Upside)